comparemela.com
Home
Live Updates
Intercept Pharmaceuticals : EASL 2023 Podium Presentation of
Intercept Pharmaceuticals : EASL 2023 Podium Presentation of
Intercept Pharmaceuticals : EASL 2023 Podium Presentation of OCA-bezafibrate Combination Planned Interim Analysis
Results from a planned interim analysis of a randomized, double- blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis
...
Related Keywords
Czech Republic ,
United States ,
Turkey ,
France ,
Belgium ,
Leuven ,
Region Flamande ,
Argentina ,
Antonio Civitarese ,
Frederik Nevens ,
Lynda Szczech ,
Alexandre Louvet ,
Vaclav Hejda ,
Cheng Zou ,
,
University Hospital In Pilsen ,
University Hospital Of Lille ,
Intercept Pharmaceuticals Inc ,
University Hospital Ku Leuven ,
Primary Biliary Cholangitis ,
Data Showed Promise With ,
Obeticholic Acid ,
Patients With Poor Response ,
Alkaline Phosphatases ,
Free Survival Demonstrated ,
External Controls ,
Range Exploration ,
Fixed Dose Combination ,